Health
FDA Approves Pritelivir for Herpes Lesions That Resist Standard Antivirals in Immunocompromised Adults
Hovilpri, a daily tablet with a new mechanism, beat investigators' choice of older drugs in a 101-person trial. It is aimed at people with transplants, blood cancers or HIV whose sores will not heal.
Oct 10, 2026
